Teleflex (TFX) – Research Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Teleflex (NYSE: TFX):

• 3/12/2025 – Teleflex had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 3/5/2025 – Teleflex had its price target lowered by analysts at Morgan Stanley from $275.00 to $191.00. They now have an “overweight” rating on the stock.
• 3/4/2025 – Teleflex was downgraded by analysts at Bank of America Co. from a “neutral” rating to an “underperform” rating. They now have a $140.00 price target on the stock, down previously from $235.00.
• 3/3/2025 – Teleflex had its price target lowered by analysts at Truist Financial Co. from $200.00 to $149.00. They now have a “hold” rating on the stock.
• 2/28/2025 – Teleflex was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $155.00 price target on the stock, down previously from $220.00.
• 2/28/2025 – Teleflex had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $140.00 price target on the stock, down previously from $255.00.
• 2/28/2025 – Teleflex was downgraded by analysts at Raymond James from an “outperform” rating to a “market perform” rating.
• 2/28/2025 – Teleflex was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 2/28/2025 – Teleflex had its price target lowered by analysts at Wells Fargo & Company from $214.00 to $146.00. They now have an “equal weight” rating on the stock.
• 2/27/2025 – Teleflex was downgraded by analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating.

Teleflex Stock Up 1.1 %

NYSE:TFX opened at $137.79 on Monday. The firm has a market capitalization of $6.39 billion, a price-to-earnings ratio of 27.39, a PEG ratio of 1.73 and a beta of 1.21. Teleflex Incorporated has a 1-year low of $128.55 and a 1-year high of $249.90. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. The business’s fifty day moving average price is $166.99 and its 200 day moving average price is $197.37.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million. On average, sell-side analysts forecast that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Friday, March 7th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Friday, March 7th. This represents a $1.36 dividend on an annualized basis and a yield of 0.99%. Teleflex’s dividend payout ratio (DPR) is currently 95.77%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TFX. Apollon Wealth Management LLC boosted its stake in shares of Teleflex by 3.7% during the 3rd quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock worth $377,000 after acquiring an additional 55 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Teleflex by 2.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 102,909 shares of the medical technology company’s stock worth $25,451,000 after acquiring an additional 2,545 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Teleflex by 364.6% during the 3rd quarter. Victory Capital Management Inc. now owns 35,370 shares of the medical technology company’s stock worth $8,748,000 after acquiring an additional 27,757 shares in the last quarter. KBC Group NV boosted its stake in shares of Teleflex by 13.2% during the 3rd quarter. KBC Group NV now owns 4,577 shares of the medical technology company’s stock worth $1,132,000 after acquiring an additional 535 shares in the last quarter. Finally, Huntington National Bank boosted its stake in shares of Teleflex by 32.5% during the 3rd quarter. Huntington National Bank now owns 310 shares of the medical technology company’s stock worth $77,000 after acquiring an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.